Predictors of hot flushes in postmenopausal women who receive raloxifene therapy.

Objective: In a previous report, we described the results of a randomized, controlled trial that evaluated the potential of raloxifene to induce or exacerbate hot flushes. Here, we provide additional analyses that were undertaken to identify potential predictors of hot flushes and to assess the clinical usefulness of various therapeutic strategies for the reduction of hot flushes in postmenopausal women who receive raloxifene therapy.

Study Design: In this randomized, double-blind, placebo-controlled study, 487 unselected postmenopausal women were assigned randomly to receive treatment for 8 months with raloxifene, which was administered either at a dose of 60 mg/d every other day for 2 months followed by 60 mg/d (slow-dose escalation) or 60 mg/d throughout (raloxifene), or placebo.

The significance of determining CA 15-3 in the cytosol of breast cancer.

The identification of tumor markers in patients who had undergone operation for breast cancer provides important information in the follow-up in addition to evaluation by clinical and visual methods. The aim of our study was to determine the clinical prospective value of CA 15-3, mucin-like carcinoma-associated antigen and carcinoembryonic antigen in preoperative measurement of serum samples in patients with primary breast cancer, and to determine CA 15-3 and steroid receptors in the cytosol of the tumor. The results show that the most exact correlation occurred between serum CA 15-3 and the different stages of the tumor.

[Therapeutic aspects of trichomonas infection of the female genitals].

Infection with trichomonas is a common event in patients in gynecologic practice. In patients in an outpatient department the incidence of trichomonas infection was 7%, in cases with other genital infections 16%. Especially in alcalic vaginal milieu and in Gardnerella infections higher rates of trichomonas could be observed.